A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
Effective SARS-CoV-2 antiviral drugs are desperately needed. The SARS-CoV-2 main protease (Mpro) appears as an attractive target for drug development. We show that the existing pharmacopeia contains many drugs with potential for therapeutic repurposing as selective and potent inhibitors of SARS-CoV-...
Guardado en:
Autores principales: | Jeremy D Baker, Rikki L Uhrich, Gerald C Kraemer, Jason E Love, Brian C Kraemer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/895a0ece70cf42ddbee160139b5c757c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
por: Alice Douangamath, et al.
Publicado: (2020) -
The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors
por: Lucia Silvestrini, et al.
Publicado: (2021) -
ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19
por: Zeynab Fakhar, et al.
Publicado: (2021) -
Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease
por: Yuxi Lin, et al.
Publicado: (2021) -
Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase
por: Syed Hani Abidi, et al.
Publicado: (2021)